NO20065107L - PGD2 reseptor antagonister for behandling av inflammatoriske sykdommer - Google Patents
PGD2 reseptor antagonister for behandling av inflammatoriske sykdommerInfo
- Publication number
- NO20065107L NO20065107L NO20065107A NO20065107A NO20065107L NO 20065107 L NO20065107 L NO 20065107L NO 20065107 A NO20065107 A NO 20065107A NO 20065107 A NO20065107 A NO 20065107A NO 20065107 L NO20065107 L NO 20065107L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- receptor antagonists
- inflammatory diseases
- pgd2 receptor
- structural formulas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Beskrevet her er forbindelser representert ved Strukturelle Formel (I) og (I-A): Også beskrevet er anvendelse av slike forbindelser for å hemme G-protein koblet reseptor referert til som kjemotiltrekkende reseptor-homolog molekyl uttrykt på Th2 eller kun "CRTH2" for behandling av inflammatoriske lidelser. Variablene i Strukturelle Formel (I) og (I-A) er definert her.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56041004P | 2004-04-07 | 2004-04-07 | |
PCT/US2005/011643 WO2005100321A1 (en) | 2004-04-07 | 2005-04-07 | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20065107L true NO20065107L (no) | 2006-12-01 |
Family
ID=34965223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20065107A NO20065107L (no) | 2004-04-07 | 2006-11-06 | PGD2 reseptor antagonister for behandling av inflammatoriske sykdommer |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1740547A1 (no) |
JP (1) | JP2007532555A (no) |
KR (1) | KR20070002085A (no) |
CN (1) | CN101018770A (no) |
AR (1) | AR048528A1 (no) |
AU (1) | AU2005233125A1 (no) |
BR (1) | BRPI0509668A (no) |
CA (1) | CA2561564A1 (no) |
CL (1) | CL2008000069A1 (no) |
CR (1) | CR8659A (no) |
EC (1) | ECSP066977A (no) |
IL (1) | IL178328A0 (no) |
MA (1) | MA28566B1 (no) |
MX (1) | MXPA06011540A (no) |
NO (1) | NO20065107L (no) |
RU (1) | RU2006138603A (no) |
TN (1) | TNSN06320A1 (no) |
TW (1) | TW200538127A (no) |
UA (1) | UA84749C2 (no) |
WO (1) | WO2005100321A1 (no) |
ZA (1) | ZA200608955B (no) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070114762A (ko) | 2005-02-24 | 2007-12-04 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 염증 질환 치료를 위한 pgd2 수용체 길항제 |
EP1717235A3 (en) * | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
RU2422442C2 (ru) | 2005-07-29 | 2011-06-27 | Ф. Хоффманн-Ля Рош Аг | Производные индол-3-ил-карбонил-пиперидина и пиперазина |
ES2618352T3 (es) | 2006-06-16 | 2017-06-21 | The Trustees Of The University Of Pennsylvania | Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética |
JP2010501567A (ja) | 2006-08-24 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | 代謝系、心血管系および他の障害の処置のためのステアロイル−CoA不飽和化酵素(SCD)阻害剤としての2−(ピラジン−2−イル)−チアゾールおよび2−(1H−ピラゾール−3−イル)チアゾール誘導体ならびに関連化合物 |
JPWO2008029924A1 (ja) | 2006-09-08 | 2010-01-21 | 大日本住友製薬株式会社 | 環状アミノアルキルカルボキサミド誘導体 |
EP2066664A1 (en) | 2006-09-22 | 2009-06-10 | Novartis AG | Heterocyclic organic compounds |
KR20090091337A (ko) | 2006-12-20 | 2009-08-27 | 노파르티스 아게 | Scd 억제제로서의 2-치환 5-원 헤테로사이클 |
JP5466507B2 (ja) | 2007-09-27 | 2014-04-09 | 興和株式会社 | テトラヒドロキノリン化合物を有効成分とする貧血の予防及び/又は治療剤 |
AU2008337342B2 (en) | 2007-12-14 | 2012-05-24 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
JP2011102241A (ja) * | 2008-03-04 | 2011-05-26 | Dainippon Sumitomo Pharma Co Ltd | 新規1−アミノカルボニルピペリジン誘導体 |
ES2617868T3 (es) | 2008-08-22 | 2017-06-20 | Baxalta GmbH | Derivados de carbonato de bencilo poliméricos |
JP2011256110A (ja) * | 2008-09-30 | 2011-12-22 | Takeda Chem Ind Ltd | ヘキサヒドロピロロキノリンの製造法 |
EP2415764A4 (en) | 2009-03-31 | 2012-08-08 | Kowa Co | PROPHYLACTIC AND / OR THERAPEUTIC AGENT AGAINST ANEMIA WITH A TETRAHYDROCHINOLINE COMPOUND AS AN ACTIVE SUBSTANCE |
GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
EP2955524A3 (en) | 2009-11-05 | 2016-03-23 | GlaxoSmithKline LLC | Novel process |
BR112013000254A2 (pt) | 2010-07-05 | 2016-05-24 | Actelion Pharmaceuticals Ltd | derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2 |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
MX2013014900A (es) | 2011-06-17 | 2014-02-17 | Merck Sharp & Dohme | Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de la molecula receptora homologa quimioatrayente expresada en celulas t auxiliares de tipo 2. |
BR112014014558A8 (pt) | 2011-12-16 | 2017-07-04 | Atopix Therapeutics Ltd | composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica |
BR112014015081A2 (pt) | 2011-12-21 | 2017-06-13 | Actelion Pharmaceuticals Ltd | derivados heterocíclicos e seu uso como moduladores do receptor d2 de prostaglandina |
EP2885307A1 (en) | 2012-07-05 | 2015-06-24 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
CA2993972A1 (en) | 2015-07-30 | 2017-02-02 | The Trustees Of The University Of Pennsylvania | Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2 |
JOP20190105A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
EA202092490A1 (ru) | 2018-04-18 | 2020-12-23 | Констеллейшен Фармасьютикалс, Инк. | Модуляторы метилмодифицирующих ферментов, композиции и их применения |
CA3100977A1 (en) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
CN113201316B (zh) * | 2021-04-25 | 2022-08-26 | 西南石油大学 | 温度/CO2/pH多重响应性乳化剂和乳状液及其应用 |
CN116425623B (zh) * | 2023-04-10 | 2024-02-13 | 大连凯飞化学股份有限公司 | 一锅法合成3,5-二氯-4-甲基苯甲酸的方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0101728A3 (en) * | 1998-03-31 | 2002-04-29 | Shionogi & Co | 5-hydroxybenzo[b]thiophene-3-carboxylic acid and their derivatives and methods for producing them |
CN1297541C (zh) * | 2001-04-30 | 2007-01-31 | 辉瑞产品公司 | 制备胆固醇酯转运蛋白抑制剂的方法 |
JP2003321471A (ja) * | 2002-04-30 | 2003-11-11 | Fuji Photo Film Co Ltd | ラクタム化合物及びその製造方法 |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
EA011385B1 (ru) * | 2002-10-04 | 2009-02-27 | Миллениум Фармасьютикалз, Инк. | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний |
CA2500083A1 (en) * | 2002-10-21 | 2004-04-29 | Warner-Lambert Company Llc | Tetrahydroquinoline derivatives as crth2 antagonists |
AU2003289207A1 (en) * | 2002-12-06 | 2004-06-30 | Kyowa Hakko Kogyo Co., Ltd. | Anti-inflammatory agent |
EP1435356A1 (en) * | 2003-01-06 | 2004-07-07 | Warner-Lambert Company LLC | Quinoline derivatives as CRTH2 antagonists |
-
2005
- 2005-04-07 WO PCT/US2005/011643 patent/WO2005100321A1/en active Application Filing
- 2005-04-07 EP EP05733968A patent/EP1740547A1/en not_active Withdrawn
- 2005-04-07 KR KR1020067023323A patent/KR20070002085A/ko not_active Application Discontinuation
- 2005-04-07 CA CA002561564A patent/CA2561564A1/en not_active Abandoned
- 2005-04-07 UA UAA200611678A patent/UA84749C2/ru unknown
- 2005-04-07 AU AU2005233125A patent/AU2005233125A1/en not_active Withdrawn
- 2005-04-07 CN CNA200580018590XA patent/CN101018770A/zh active Pending
- 2005-04-07 BR BRPI0509668-5A patent/BRPI0509668A/pt not_active IP Right Cessation
- 2005-04-07 MX MXPA06011540A patent/MXPA06011540A/es not_active Application Discontinuation
- 2005-04-07 JP JP2007507467A patent/JP2007532555A/ja active Pending
- 2005-04-07 AR ARP050101369A patent/AR048528A1/es unknown
- 2005-04-07 RU RU2006138603/04A patent/RU2006138603A/ru not_active Application Discontinuation
- 2005-04-07 TW TW094111008A patent/TW200538127A/zh unknown
-
2006
- 2006-09-27 IL IL178328A patent/IL178328A0/en unknown
- 2006-09-27 CR CR8659A patent/CR8659A/es not_active Application Discontinuation
- 2006-10-06 TN TNP2006000320A patent/TNSN06320A1/en unknown
- 2006-10-27 ZA ZA200608955A patent/ZA200608955B/xx unknown
- 2006-11-02 MA MA29430A patent/MA28566B1/fr unknown
- 2006-11-06 NO NO20065107A patent/NO20065107L/no not_active Application Discontinuation
- 2006-11-08 EC EC2006006977A patent/ECSP066977A/es unknown
-
2008
- 2008-01-10 CL CL200800069A patent/CL2008000069A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200608955B (en) | 2009-05-27 |
BRPI0509668A (pt) | 2007-10-09 |
AR048528A1 (es) | 2006-05-03 |
CR8659A (es) | 2007-06-08 |
RU2006138603A (ru) | 2008-05-20 |
MXPA06011540A (es) | 2007-01-26 |
CL2008000069A1 (es) | 2008-05-16 |
KR20070002085A (ko) | 2007-01-04 |
EP1740547A1 (en) | 2007-01-10 |
CA2561564A1 (en) | 2005-10-27 |
IL178328A0 (en) | 2007-02-11 |
UA84749C2 (ru) | 2008-11-25 |
CN101018770A (zh) | 2007-08-15 |
ECSP066977A (es) | 2006-12-29 |
AU2005233125A1 (en) | 2005-10-27 |
MA28566B1 (fr) | 2007-05-02 |
WO2005100321A1 (en) | 2005-10-27 |
JP2007532555A (ja) | 2007-11-15 |
TNSN06320A1 (en) | 2008-02-22 |
TW200538127A (en) | 2005-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20065107L (no) | PGD2 reseptor antagonister for behandling av inflammatoriske sykdommer | |
NO20051566L (no) | PGD2 reseptor antagonister for behandling av inflammatoriske sykdommer | |
NO20070489L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
BRPI0408369A (pt) | derivados de indol úteis para o tratamento de doenças | |
NO20070466L (no) | Pyrrolopyrimidin og pyrrolopyridinderivater substituert med en cyklisk aminogruppe som CRF antagonister | |
NO20064151L (no) | Nye forbindelser | |
NO20083411L (no) | Indaneddiksyrederivater og deres anvendelse som farmasoytiske midler, intermediater og fremgangsmater for fremstilling | |
NO20070467L (no) | Pyrrolopyrimidin og pyrrolopyridinderivater substituert med tetrahydropyridin som CRF antagonister | |
NO20063928L (no) | Substituerte kinolinforbindelser | |
CY1106894T1 (el) | Παραγωγα σουλφοναμιδιων για την αγωγη ασθενειων | |
DE602005013822D1 (de) | Cycloalkylaminderivate | |
EA200200921A1 (ru) | Полуамиды малоновой кислоты и их производные в качестве лигандов тиреоидных рецепторов | |
ATE250577T1 (de) | Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten | |
NO20065678L (no) | 3-(4-heteroarylcykloheksylamino) cyklopentankarboksamider som modulatorer for kjemokinreseptorer. | |
MX2007003335A (es) | Acidos aceticos de bencimidazol que muestran antagonismo de receptor crth2 y usos de los mismos. | |
WO2005018529A3 (en) | Phenoxiacetic acid derivatives | |
NO20053792L (no) | Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander | |
EA201171197A8 (ru) | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения | |
NO20052595L (no) | Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser. | |
NO20076059L (no) | 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer | |
NO20051503L (no) | Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme. | |
NO20065230L (no) | Kondenserte pyridinderivater anvendelige som A28 adenosinreseptorantagonister | |
NO20065983L (no) | Forbindelser og sammensetninger som PPAR modulatorer | |
ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten | |
NO20076515L (no) | Hydantoinforbindelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |